Clinical Trials Sponsored by Medrio, Inc

Total 36946 results

IRIS Media Inc

Completed

ASD Parent Trainer: Online Coaching for Parents of Children With Autism (APT)

Autism Disorder

United States
MEDRx USA, Inc.

Completed

Etodolac-Lidocaine Patch in the Treatment of Acute Low Back Pain

Low Back Pain

United States
MEDRx USA, Inc.

Completed

MRX-7EAT Etodolac-Lidocaine Topical Patch in the Treatment of Tendonitis and Bursitis of the Shoulder

Bursitis | Acute Tendonitis

United States
MEDRx USA, Inc.

Completed

Safety & Efficacy Study of MRX-7EAT Patch in the Treatment of Pain of the Shoulder

Shoulder Pain | Bursitis | Tendonitis

United States
MEDRx USA, Inc.

Completed

MRX-7EAT Etodolac-Lidocaine Topical Patch in the Treatment of Ankle Sprains

Ankle Sprains

United States
MEDRx USA, Inc.

Completed

Etodolac-lidocaine Patch in Subjects Experiencing Acute Delayed Onset Muscle Soreness

Acute Delayed Onset Muscle Soreness (DOMS)

United States
Medtronic Endovascular
MEDRAD, Inc.

Completed

Atherectomy Followed by a Drug Coated Balloon to Treat Peripheral Arterial Disease (DEFINITIVE AR)

Peripheral Arterial Disease | Claudication

Belgium
MedSIR
Daiichi Sankyo, Inc.

Not yet recruiting

T-DXd Therapy for HER2-low Breast Cancer Patients With Brain Metastases (TUXEDO-4)

Breast Cancer | Metastatic Breast Cancer
MedSIR
Daiichi Sankyo, Inc.

Completed

DS-8201a for trEatment of aBc, BRain Mets, And Her2[+] Disease (DEBBRAH)

Advanced Breast Cancer | HER2-positive Breast Cancer | Brain Metastases | Leptomeningeal Metastasis

Spain, Portugal
MedSIR
Stemline Therapeutics, Inc.

Not yet recruiting

Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i. (ADELA)

Advanced Breast Cancer | ER-positive Breast Cancer | HER2-negative Breast Cancer | ESR1 Gene Mutation
MedSIR
MacroGenics; Seagen Inc.

Withdrawn

Margetuximab Plus Tucatinib and Capecitabine in HER2-positive Metastatic Breast Cancer (MARGARET)

Advanced Breast Cancer | Metastatic Breast Cancer | HER2-positive Breast Cancer
Merit Medical Systems, Inc.

Recruiting

GAE Using Embosphere Microspheres vs Corticosteroid Injections for Treatment of Symptomatic Knee OA (MOTION)

Knee Osteoarthritis

Canada, United States, Brazil, United Kingdom
Merit Medical Systems, Inc.

Recruiting

EmboCube Gelatin Embolization to Control Bleeding or Hemorrhaging

Hemorrhage | Bleeding Hemorrhage

France, Australia
Merit Medical Systems, Inc.

Recruiting

Merit WRAPSODY™ Endoprosthesis for Treatment of Stenosis or Occlusion (WRAP)

Venous Stenosis | Venous Occlusion

Israel, Netherlands, Australia, United Kingdom, Brazil, Germany, New Zealand, Portugal, Greece
Merit Medical Systems, Inc.

Terminated

HepaSphere/Quadrasphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Cancer (HiQuality)

Hepatocellular Carcinoma

United States, France, Belgium, Greece, Italy
Merit Medical Systems, Inc.

Terminated

Prostate Artery Embolization With Embosphere Microspheres Compared to TURP for Benign Prostatic Hyperplasia

Benign Prostatic Hyperplasia

United States
Merit Medical Systems, Inc.

Not yet recruiting

Bearing nsPVA Embolization for Uterine Artery Embolization

Uterine Fibroid
Merit Medical Systems, Inc.

Recruiting

Streamlined Localization Using SCOUT® at Biopsy (STREAMLoc )

Breast Cancer

Canada
Merit Medical Systems, Inc.

Completed

Surfacer System to Facilitate Access in Venous Occlusions (SAVE)

Chronic Venous Thrombosis | Venous Thrombosis Upper Extremity | Venous Thrombosis Upper Extremity Superficial Veins

Austria, Germany, Italy
Merit Medical Systems, Inc.

Completed

Embosphere® PROstate Post Market Study (PROstate)

Lower Urinary Tract Symptoms | Benign Prostatic Hyperplasia

United States, United Kingdom, Italy, France
Merit Medical Systems, Inc.

Completed

HepaSphere™ Microspheres Prospective Registry (mCRC)

Metastatic Colorectal Cancer

France, Greece
Merit Medical Systems, Inc.

Completed

The Merit WRAPSODY™ Endovascular Stent Graft

Venous Stenosis | Venous Occlusion

United Kingdom, Greece
Merit Medical Systems, Inc.

Completed

HeRO Vascular Access Device Post Market Procedural Survey Protocol (PPS)

End Stage Renal Disease
Medco Health Solutions, Inc.

Terminated

Genotype Guided Comparison of Clopidogrel and Prasugrel Outcomes Study (GeCCO)

Cardiovascular Disease

United States
Merit Medical Systems, Inc.
CryoLife, Inc.

Completed

Hemodialysis Reliable Outflow (HeRO) Vascular Access Patency Study

Renal Failure Chronic Requiring Hemodialysis

United States
Merit Medical Systems, Inc.
CryoLife, Inc.

Withdrawn

Data Collection Registry of the HeRO Graft for End Stage Renal Disease Patients Receiving Hemodialysis

End Stage Renal Failure on Dialysis

United States
Merit Medical Systems, Inc.
CryoLife, Inc.

Completed

HeRO Graft Compared to Permanent Catheters for End Stage Renal Disease (ESRD) Patients Receiving Hemodialysis

End Stage Renal Disease (ESRD)

United States
DFINE Inc.

Withdrawn

Evaluation of Vertebral Compression Fracture Fixation With RF Kyphoplasty in Patients With Multiple Myeloma (MM)

Multiple Myeloma | Compression Fracture of Vertebral Column
DFINE Inc.

Withdrawn

The PRIORi-T Trial--Prospective Randomized Investigation of Radiofrequency Targeted Vertebral Augmentation (PRIORi-T)

Painful Osteoporotic Vertebral Compression Fractures (VCF)

United States
DFINE Inc.

Completed

The STAR Prospective Clinical Series (PCS)

Metastasis to Vertebral Column

United States
DFINE Inc.

Terminated

Evaluating Clinical Outcomes of Targeted Radiofrequency Ablation and Kyphoplasty (Also Known as Vertebral Augmentation) to Treat Painful Metastatic Vertebral Body Tumors (EU-STAR)

Metastatic Lesions in Vertebral Bodies

Germany, Italy, France
University of Rochester
MEDRAD, Inc.

Completed

Study of the SafeSeal(TM) Hemostasis Patch Following Percutaneous Coronary Artery and Peripheral Vascular Interventions

Coronary Artery Disease | Peripheral Vascular Disease

United States
MedSIR
AstraZeneca; Daiichi Sankyo, Inc.

Completed

Real-World Data of Clinicopathological Characteristics and Management of Breast Cancer Patients According to HER2 Status (RosHER)

Metastatic Breast Cancer | Early Breast Cancer | Locally Advanced Breast Cancer

Spain
Merit Medical Systems, Inc.

Recruiting

US Post-Market Surveillance Study of the Surfacer System

Venous Disease

United States
Merit Medical Systems, Inc.

Active, not recruiting

The Merit WRAPSODY AV Access Efficacy Study (WAVE) (WAVE)

Venous Stenosis | Venous Occlusion

United States, United Kingdom, Canada, Brazil
Merit Medical Systems, Inc.

Withdrawn

The Merit WRAPSODY™ Endovascular Stent Graft for Treatment of Iliac Artery Occlusive Disease

Peripheral Arterial Disease | Iliac Artery Occlusion | Iliac Artery Disease | Stenosis of Artery
Merit Medical Systems, Inc.

Completed

Post Marketing Surveillance of the CentrosFLO™ Tunneled IJ Catheter (MCENPS)

Pain; Dialysis Catheter

United States
Merit Medical Systems, Inc.
DFINE Inc.

Terminated

Evaluation of t-RFA and RF-TVA Prior to/Following Radiation Therapy to Treat Painful Metastatic Vertebral Body Tumor(s) (STARRT)

Metastatic Lesions in Vertebral Bodies

United States
Merit Medical Systems, Inc.
DFINE Inc.

Terminated

The STAR™ Tumor Ablation Registry

Metastatic Lesions in Vertebral Bodies

United States
USGI Medical
Centro Medico Teknon; Hospital Universitario Madrid Sanchinarro

Completed

A Post-Market Surveillance Study of Using the g-Cath EZ for Treating Obesity

Treatment of Obesity

Spain
Ultragenyx Pharmaceutical Inc
Mereo BioPharma

Active, not recruiting

Study to Assess Dose, Efficacy and Safety of Setrusumab in Participants With Osteogenesis Imperfecta (Orbit)

Osteogenesis Imperfecta

United States, Turkey, Germany, United Kingdom, Italy, Portugal, Canada, Australia, Argentina, France, Netherlands, Poland
Ultragenyx Pharmaceutical Inc
Mereo BioPharma

Terminated

Long-term Extension Study of Setrusumab in Adults With Type I, III, or IV Osteogenesis Imperfecta

Osteogenesis Imperfecta

United States
OncoMed Pharmaceuticals, Inc.

Completed

A Phase 1b/2 Study of OMP-59R5 (Tarextumab) in Combination With Nab-Paclitaxel and Gemcitabine in Subjects With Previously Untreated Stage IV Pancreatic Cancer (ALPINE)

Stage IV Pancreatic Cancer

United States
OncoMed Pharmaceuticals, Inc.

Completed

A Phase 1 Dose Escalation Study of OMP-21M18 in Subjects With Solid Tumors

Solid Tumors

United States
OncoMed Pharmaceuticals, Inc.

Terminated

A Phase 1b/2 Study of OMP-59R5 (Tarextumab) in Combination With Etoposide and Platinum Therapy (PINNACLE)

Stage IV Small Cell Lung Cancer

United States
OncoMed Pharmaceuticals, Inc.

Completed

A Dose Escalation Study of OMP-52M51 in Subjects With Lymphoid Malignancies

Relapsed or Refractory Lymphoid Malignancies

United States
OncoMed Pharmaceuticals, Inc.

Completed

Dose Escalation Study of OMP-54F28 in Combination With Nab-Paclitaxel and Gemcitabine in Patients With Previously Untreated Stage IV Pancreatic Cancer

Pancreatic Cancer | Stage IV Pancreatic Cancer

United States
OncoMed Pharmaceuticals, Inc.

Completed

A Phase 1b Study of OMP-305B83 Plus Paclitaxel in Subjects With Ovarian, Peritoneal or Fallopian Tube Cancer

Cancer Ovaries | Cancer Peritoneal | Cancer, Fallopian Tube

United States
OncoMed Pharmaceuticals, Inc.

Completed

A Phase 1a/b Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of OMP-131R10

Refractory Solid Tumors | Advanced Relapsed Tumors

United States
OncoMed Pharmaceuticals, Inc.

Completed

Dose Escalation Study of OMP-54F28 in Combination With Sorafenib in Patients With Hepatocellular Cancer

Liver Cancer | Hepatocellular Cancer

United States

Clinical Trials Sponsored by Medrio, Inc

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Serbia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations